Andrew C. Rawstron

Leeds, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

Journal: British journal of haematology

Published: December 08, 2025

Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study.

Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study.

Journal: Haematologica

Published: August 24, 2025

Measurable/Minimal Residual Disease: What Method and What Cut-Off?

Measurable/Minimal Residual Disease: What Method and What Cut-Off?

Journal: Hematology/oncology clinics of North America

Published: July 31, 2025

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: June 16, 2025

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.

Journal: Blood cancer journal

Published: March 09, 2025

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.

Journal: Lancet (London, England)

Published: February 18, 2025

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Journal: The New England journal of medicine

Published: December 11, 2023

Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748.

Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748.

Journal: Leukemia

Published: July 19, 2023

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: January 16, 2023

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Journal: Leukemia

Published: May 03, 2022

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome.

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome.

Journal: ACR open rheumatology

Published: February 28, 2022

Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors.

Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors.

Journal: American journal of hematology

Published: November 25, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026